NICE approves ombitasvir, paritaprevir, ritonavir with or without dasabuvir to treat adult HCV
1 February 2016. Related: Hepatitis coinfection.
On 25 November, NICE published guidance for use of ombitasvir, paritaprevir, ritonavir with or without dasabuvir, to treat adults with hepatitis C genotype 1 or 4. [1]
A summary of recommendations is included below in Table 1, but please refer to the full NICE document for details.
This is dependent on the company providing these drugs at the same price or lower than that agreed with the Commercial Medicines Unit.
Ombitasvir/paritaprevir/ritonavir is a single tablet formulation has the brand name Viekirax. Dasabuvir has the brand name Exviera.
All drugs are manufactured by AbbVie.
| HCV genotype, liver disease stage | Treatment | Duration (weeks) | Recommendation according to treatment history | |
|---|---|---|---|---|
| Untreated | Treated | |||
| 1a, without cirrhosis | Ombitasvir-paritaprevir-ritonavir with dasabuvir and ribavirin | 12 | Recommended | |
| 1a, with compensated cirrhosis | Ombitasvir-paritaprevir-ritonavir with dasabuvir and ribavirin | 24 | Recommended | |
| 1b, without cirrhosis | Ombitasvir-paritaprevir-ritonavir with dasabuvir | 12 | Recommended | |
| 1b, with compensated cirrhosis | Ombitasvir-paritaprevir-ritonavir with dasabuvir and ribavirin | 12 | Recommended | |
| 4, without cirrhosis | Ombitasvir-paritaprevir-ritonavir with ribavirin | 12 | Recommended | |
| 4, with compensated cirrhosis | Ombitasvir-paritaprevir-ritonavir with ribavirin | 24 | Recommended | |
| Abbreviation: HCV, hepatitis C virus. Treated – the person’s hepatitis C has not adequately responded to interferon-based treatment. | ||||
Comment
A price for ombitasvir-paritaprevir-ritonavir is approximately £32,200 for 12 weeks and £64,400 for 24 weeks of treatment, both excluding VAT. The price for dasabuvir is £2800 and £5600 for 12 and 24 week course respectively (excluding VAT).
The guidance notes that a nationally available price reduction for ledipasvir/sofosbuvir has been agreed with the Commercial Medicines Unit, but also that this was not considered as part of the submission. No details of the reduced price have been published.
Treatment should be available on the NHS within 3 months of the guidance being issued.
Reference:
NICE guidance. Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C. NICE technology appraisal guidance [TA365] Published date: November 2015
http://www.nice.org.uk/guidance/ta365